Arcturus Therapeutics Holdings Inc. ARCT revenue by segment, product and geography
In its fiscal year ending 2025-12-31, Arcturus Therapeutics Holdings Inc. reported revenue across 2 products and services; the largest, Collaboration Revenue, was $67.2M, 81.9% of the filed sum (-51.4% against the prior period in the same filing).
Reported segment mix
figures as filed · share of the filed sum · change vs the prior period in the same filing- Collaboration Revenue$67.2M81.9%-51.4% yoy
- Grant$14.8M18.1%+6.4% yoy
Members sum to the consolidated $82M for this period.
- Outside the United States$67.1M100.0%-51.5% yoy
Members sum to $67.1M against $82M consolidated (residual $14.9M) - eliminations or corporate lines the filer did not tag on this axis.
- Grant$1.45M70.4%-62.8% yoy
- Collaboration Revenue$610K29.6%-97.6% yoy
Change is against the same quarter a year earlier, as reported in the same 10-Q.
Source: SEC DERA Financial Statement and Notes data sets. Dimensional XBRL facts on the business-segment, product/service and geographic axes; the engine keeps the accession of every figure. Descriptive and educational, not advice.
About these figures
Companies tag segment, product and geographic revenue as dimensional XBRL facts in their 10-K and 10-Q filings. The SEC publishes those facts in its DERA Financial Statement and Notes data sets; TrendNalysis ingests each monthly file and serves the facts exactly as filed, keyed to the accession of the filing. Shares are of the filed sum. Where a filer tags more than one breakdown on one axis, the sum exceeds consolidated revenue and no shares are computed; where the members do not add up to the consolidated figure, the residual is stated rather than hidden. Missing is never zero.
Descriptive and educational; not investment advice. Methodology and data lineage.